SLC10A1 as A Potential Drug Target for Parkinson's Disease (G6554)

Target Name: SLC10A1

NCBI ID: G6554

SLC10A1

SLC10A1 as A Potential Drug Target for Parkinson's Disease

SLC10A1: A Potential Drug Target and Biomarker for Na/Taurocholate Cotransporting Polypeptide in Parkinson's Disease

Introduction

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. The underlying cause of Parkinson's disease is the neurodegeneration of dopamine-producing neurons in the brain, which results in the loss of motor and cognitive functions. One of the leading hypotheses in the development of Parkinson's disease is the role of the sodium/taurocholate cotransporting polypeptide (SLC10A1) in the regulation of dopamine homeostasis. SLC10A1 is a transmembrane protein that is expressed in various tissues and cell types, including brain. Its function in the regulation of sodium and tau homeostasis is of great interest in the development of new therapeutic strategies for Parkinson's disease.

SLC10A1 Regulates Sodium and Tau Homeostasis

Sodium and tau are essential ions that play crucial roles in various cellular processes, including muscle and nerve function, as well as neurotransmitter synthesis and release. Sodium is responsible for the rapid depolarization of the neuronal membrane during the initiation of an action potential, while tau is involved in the regulation of the stability of the neuronal cytoskeleton. The regulation of sodium and tau homeostasis is critical for the normal function of neurons and the development of various neurological disorders, including Parkinson's disease.

SLC10A1 is involved in the regulation of sodium and tau homeostasis by facilitating the transport of sodium and tau across the membrane of the heterodimeric sodium/tau transporter (SST). SST is a protein that consists of two subunits, Na+-Tau4 and NAt- Tau4. Na+-Tau4 is the catalytic subunit, while NAt-Tau4 is the non-catalytic subunit. SLC10A1 is a critical modifier of the NAt-Tau4 subunit, which is responsible for the regulation of sodium and tau homeostasis.

SLC10A1-mediated regulation of sodium and tau homeostasis is essential for the normal function of neurons and the development of various neurological disorders. The disruption of SLC10A1 function has been implicated in the development of various neurodegenerative disorders, including Parkinson's disease.

Potential Therapeutic Strategies for SLC10A1-Induced Parkinson's Disease

The regulation of sodium and tau homeostasis by SLC10A1 is a promising target for the development of new therapeutic strategies for Parkinson's disease. One potential approach is the inhibition of SLC10A1 function to reduce the sodium/tau imbalance that is thought to contribute to the development of Parkinson's disease. disease.

Anti-inflammatory agents, such asoids, have been shown to be effective in reducing inflammation and improving the symptoms of Parkinson's disease. Oids are derived from the persimmon fruit and have been shown to have anti-inflammatory and neuroprotective effects. Therefore, oids may be an attractive candidate for the treatment of Parkinson's disease.

Another therapeutic potential approach is the use of neurotransmitter precursors that can restore the levels of dopamine in the brain. The neurotransmitter precursors, such as L-tyrosine, have been shown to have neuroprotective effects and may be an attractive candidate for the treatment of Parkinson's disease.

In conclusion, SLC10A1 is a protein that is involved in the regulation of sodium and tau homeostasis and has

Protein Name: Solute Carrier Family 10 Member 1

Functions: As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins (PubMed:8132774, PubMed:14660639, PubMed:24867799, PubMed:34060352). It is strictly dependent on the extracellular presence of sodium (PubMed:8132774, PubMed:14660639, PubMed:24867799, PubMed:34060352). It exhibits broad substrate specificity and transports various bile acids, such as taurocholate, cholate, as well as non-bile acid organic compounds, such as estrone sulfate (PubMed:14660639, PubMed:34060352). Works collaboratively with the ileal transporter (NTCP2), the organic solute transporter (OST), and the bile salt export pump (BSEP), to ensure efficacious biological recycling of bile acids during enterohepatic circulation (PubMed:33222321)

The "SLC10A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC10A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets